A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

• Status: Not yet recruiting
• Trial end date: 2026-12-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to evaluate the efficacy and the safety of two doses of ZSP1601 for 48 weeks versus placebo in adult NASH patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Raynovent Biotech Co., Ltd

Criteria

Inclusion Criteria:

1. NASH histological diagnosis on a liver biopsy performed ≤ 24 weeks before randomization, and NAS≥4 (at least 1 point each in inflammation and ballooning), and fibrosis score F2 or F3, and no other chronic liver disease

2. Subjects having given her/his written informed consent

3. Good compliance with the protocol and agree to have liver biopsy performed

4. Subjects (including their partners) agreed to use effective contraception throughout the study period and up to 24 weeks after discontinuation

Exclusion Criteria:

1. History of cirrhosis or liver biopsy suggestive of cirrhosis

2. Metabolic surgery or new technology treatment for weight loss within 5 years prior to randomization or planned during the study period

3. Type 1 diabetes

4. HIV infection

5. Patients with severe or uncontrollable underlying diseases, unsuitable for treatment with ZSP1601, unable to complete study follow-up, or likely to affect the evaluation of trial results judged by investigator

6. Previous malignancy within 5 years

7. Treatment with hepatoprotective drugs

8. Excessive alcohol consumption for 12 or more consecutive weeks within 1 year prior to screening

9. Pregnant and lactating women or those with a positive serum pregnancy test.